Author: admin

The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2032. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN market.

A recent report titled, “Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Market Insight, Epidemiology And Market Forecast – 2032” by DelveInsight, provides a comprehensive analysis of BPDCN epidemiology, treatment landscape, and market trends across the 7MM, which includes the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The US leads the market with the largest annual patient population diagnosed with BPDCN, primarily due to increased awareness campaigns and improved diagnostic tools that enhance early detection rates.

BPDCN is a rare and aggressive hematologic cancer that originates from plasmacytoid dendritic cells. It accounts for less than 1% of all hematologic malignancies and is characterized by rapid progression and a poor prognosis. The disease primarily affects older adults, with a median age of diagnosis around 66 years. Additionally, BPDCN has a higher prevalence among males, and individuals of Caucasian descent are slightly more affected than those from other demographics.

Download the BPDCN market report to understand which factors are driving the BPDCN treatment market @ BPDCN Market Trends

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline Therapeutics/Menarini Group), a targeted cytotoxin, was approved by the FDA in December 2018 as the first and only targeted therapy for BPDCN.

Although treatment options for BPDCN are currently limited, several promising experimental therapies are under investigation. Several anti-CD123 CAR-T therapies are emerging as potential breakthroughs, utilizing genetically engineered T cells to target CD123, owing to the success of ELZONRIS.

Dive deeper into the evolving BPDCN treatment landscape and uncover key innovations from targeted cytotoxins to next-gen CD123 CAR-T therapies transforming patient outcomes

Combination therapies are also gaining traction, such as CD123-targeted agents combined with hypomethylating drugs like azacitidine and BCL-2 inhibitors like venetoclax, which have shown the potential to enhance antitumor responses. Furthermore, advancements in allogeneic hematopoietic stem cell transplantation (allo-HCT) are refining patient selection criteria and conditioning regimens to improve outcomes for patients who achieve remission. In March 2025, Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have BPDCN.

Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the BPDCN treatment landscape. Visit BPDCN Recent Developments

Looking ahead, the BPDCN market in the 7MM is projected to experience significant growth over the next decade as stakeholders address unmet needs through innovation and collaboration. With ongoing advancements in targeted therapies and increasing awareness among clinicians and patients alike, the market landscape for this rare malignancy is expected to expand.

Table of Contents

Related Reports

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Malignancy Pipeline Insight

Blastic Plasmacytoid Dendritic Cell Neoplasm Pipeline Insight provides comprehensive insights about the BPDCN pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the BPDCN manufacturers, including Genentech/AbbVie, Sanofi (NASDAQ: SAN), and ImmunoGen (NASDAQ: IMGN), among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BPDCN Market Set for Robust Growth Through 2032 Driven by Targeted Therapies and Rising Disease Awareness | DelveInsight

“Sjogren’s Syndrome Treatment Market”

(Albany, USA) DelveInsight’s “Sjogren’s syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sjogren’s syndrome, historical and forecasted epidemiology as well as the Sjogren’s syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sjogren’s syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Sjogren’s syndrome market dynamics.

The Sjogren’s syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Sjogren’s syndrome market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Sjogren’s syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Sjogren’s syndrome market.

To Know in detail about the Sjogren’s syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sjogren’s syndrome Market Insights

Some of the key facts of the Sjogren’s syndrome Market Report:

• The Sjogren’s syndrome market size was valued ~USD 1,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Novartis and Amgen are leading companies in the Sjogren’s syndrome market, with their drugs CFZ533 (iscalimab) and VIB4920 (dazodalibep) projected to achieve the highest revenue across the 7MM by 2034.
• Across the 7MM, approximately 1.5 million diagnosed prevalent cases of Sjogren’s syndrome were recorded in 2023, with this number anticipated to grow over the forecast period (2024–2034).
• In the US, antigen-specific cases were most commonly associated with auto-antibodies positivity, followed by anti-Ro/SSA positivity and anti-La/SSB positivity in 2023.
• In 2023, the United States recorded the highest number of treated cases of Sjogren’s syndrome, while Japan reported the lowest, with approximately 54,000 treated cases. These figures are projected to increase by 2034.
• Within the EU4 and the UK, Sjogren’s syndrome predominantly affected females, with the United Kingdom reporting the highest number of gender-specific cases in 2023.
• Sjogren’s Syndrome companies working in the treatment market are Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and others, are developing therapies for the Sjogren’s Syndrome treatment
• Emerging Sjogren’s Syndrome therapies in the different phases of clinical trials are- R-2487, BMS-986325, RSLV-132, CFZ533, VIB4920, VAY736, Dazodalibep (VIB4920), OXERVATE (cenegermin), Tivanisiran (SYL1001), Lusvertikimab (formerly OSE-127), Nipocalimab, and others are expected to have a significant impact on the Sjogren’s Syndrome market in the coming years.
• In March 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to its investigational therapy, nipocalimab, for treating adults with moderate-to-severe Sjögren’s disease (SjD). This follows the Breakthrough Therapy designation (BTD) received for the same therapy late last year. Presently, there are no advanced treatments approved specifically for this condition.
• In November 2024, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to nipocalimab for treating adults with moderate-to-severe Sjögren’s disease (SjD), a chronic autoantibody condition with significant prevalence and no approved advanced treatments available. Nipocalimab is the first investigational therapy to receive this designation for SjD. This marks the second BTD granted for nipocalimab, following the February designation for treating alloimmunized pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN).
• In June 2024, Johnson & Johnson reported results from the Phase II DAHLIAS dose-ranging study, where its monoclonal antibody nipocalimab showed significant improvements in Sjögren’s disease (SjD) activity in patients. DAHLIAS is a randomized, multicenter, placebo-controlled, double-blind trial that assessed the effects of nipocalimab in adults with primary SjD, a chronic and debilitating autoimmune disorder.

Learn more about Sjogren’s syndrome treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Sjogren’s syndrome Treatment Market

Sjogren’s syndrome Overview

Sjogren’s syndrome is a chronic autoimmune disorder that primarily targets the body’s moisture-producing glands, leading to symptoms such as dry eyes and dry mouth. Sjogren’s syndrome affects millions of individuals worldwide, with a higher prevalence in middle-aged women. This condition can occur as a primary disease or secondary to other autoimmune disorders like rheumatoid arthritis or lupus. Sjogren’s syndrome is caused by the immune system mistakenly attacking healthy tissues, particularly the salivary and lacrimal glands.

Sjogren’s syndrome symptoms include fatigue, joint pain, and swelling, dry skin, vaginal dryness, persistent cough, and swollen salivary glands. In severe cases, Sjogren’s syndrome can affect internal organs such as the kidneys, lungs, liver, and nervous system. Diagnosis of Sjogren’s syndrome involves blood tests for autoantibodies like anti-SSA/Ro and anti-SSB/La, as well as eye and salivary gland evaluations.

Sjogren’s syndrome treatment focuses on symptom management, using artificial tears, saliva substitutes, immunosuppressants, and anti-inflammatory medications. Early detection and personalized therapy can improve the quality of life for patients with Sjogren’s syndrome. Ongoing research into Sjogren’s syndrome pathogenesis and innovative therapies offers hope for more effective treatment options in the future. Sjogren’s syndrome requires a multidisciplinary care approach for optimal disease management.

Sjogren’s syndrome Epidemiology Segmentation:

The Sjogren’s syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Sjogren’s syndrome
• Prevalent Cases of Sjogren’s syndrome by severity
• Gender-specific Prevalence of Sjogren’s syndrome
• Diagnosed Cases of Episodic and Chronic Sjogren’s syndrome

Download the report to understand which factors are driving Sjogren’s syndrome epidemiology trends @ Sjogren’s syndrome Epidemiological Insights

Sjogren’s Syndrome Market Outlook

The Sjogren’s Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Sjogren’s Syndrome market trends by analyzing the impact of current Sjogren’s Syndrome therapies on the market and unmet needs, and drivers, barriers, and demand for better technology

This segment gives a thorough detail of the Sjogren’s Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sjogren’s Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Sjogren’s syndrome market is driven by several factors, including the rising prevalence of autoimmune disorders, increased awareness and early diagnosis, and advancements in immunology and biologic therapies. As more patients and healthcare professionals recognize the chronic nature and systemic impact of Sjogren’s syndrome, the demand for effective treatment options continues to grow. Ongoing research into disease mechanisms has led to the development of targeted therapies, such as immunomodulators and biologics, which offer hope for improved symptom control and disease management. Additionally, government initiatives and healthcare investments in autoimmune disease research further support market expansion.

However, the Sjogren’s syndrome market also faces significant barriers. One of the primary challenges is the lack of a definitive cure and the limited availability of disease-specific therapies, with most treatments focusing only on symptom relief. Delayed diagnosis due to the overlapping symptoms with other conditions also hinders timely intervention. Furthermore, high costs of biologics, limited reimbursement policies in certain regions, and inadequate clinical trial data for emerging therapies restrict widespread adoption. Despite these obstacles, continued advancements in biotechnology and increased collaborations between pharmaceutical companies and research institutions are expected to address current limitations and drive future growth in the Sjogren’s syndrome market.

According to DelveInsight, the Sjogren’s syndrome market in 7MM is expected to witness a major change in the study period 2020-2034.

Sjogren’s syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sjogren’s syndrome market or expected to get launched during the study period. The analysis covers Sjogren’s syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sjogren’s syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sjogren’s syndrome Therapies and Key Companies

• SALAGEN (pilocarpine): ADVANZ Pharma
• EVOXAC (cevimeline): Daiichi Sankyo
• CFZ 533 (iscalimab): Novartis
• VIB4920 (dazodalibep): Amgen
• SOTYKTU (deucravacitinib): Bristol Myers Squibb
• VAY736 (ianalumab): Novartis
• OXERVATE (cenegermin): Dompe Farmaceutici

To know more about Sjogren’s syndrome treatment, visit @ Sjogren’s syndrome Medications and Companies

Sjogren’s syndrome Market Drivers

• Increasing Prevalence
• Advancements in Diagnostics
• Sjogren’s syndrome Pipeline Therapies
• Supportive Regulatory Environment
• Growing Awareness

Sjogren’s syndrome Market Barriers

• Limited Treatment Options
• High Treatment Costs
• Side Effects of Therapies
• Delayed Diagnosis
• Lack of Awareness

Scope of the Sjogren’s syndrome Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Sjogren’s syndrome Companies: Rise Therapeutics, Bristol-Myers Squibb (NYSE: BMY), Resolve Therapeutics, Novartis (SWX: NOVN), Horizon Therapeutics (acquired by Amgen (NASDAQ: AMGN)), Dompé Farmaceutici, Sylentis, OSE Immunotherapeutics (EPA: OSE), Servier, and Johnson & Johnson (NYSE: JNJ), among others.
• Key Sjogren’s syndrome Therapies: SALAGEN (pilocarpine), EVOXAC (cevimeline), CFZ 533 (iscalimab), VIB4920 (dazodalibep), SOTYKTU (deucravacitinib), VAY736 (ianalumab), OXERVATE (cenegermin), and others
• Sjogren’s syndrome Therapeutic Assessment: Sjogren’s syndrome current marketed and Sjogren’s syndrome emerging therapies
• Sjogren’s syndrome Market Dynamics: Sjogren’s syndrome market drivers and Sjogren’s syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Sjogren’s syndrome Unmet Needs, KOL’s views, Analyst’s views, Sjogren’s syndrome Market Access and Reimbursement

Learn more about the emerging Sjogren’s syndrome therapies & key companies at: Sjogren’s syndrome Clinical Trials and Pipeline Analysis

Table of Contents

1. Sjogren’s syndrome Market Report Introduction

2. Executive Summary for Sjogren’s syndrome

3. SWOT analysis of Sjogren’s syndrome

4. Sjogren’s syndrome Patient Share (%) Overview at a Glance

5. Sjogren’s syndrome Market Overview at a Glance

6. Sjogren’s syndrome Disease Background and Overview

7. Sjogren’s syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Sjogren’s syndrome

9. Sjogren’s syndrome Current Treatment and Medical Practices

10. Sjogren’s syndrome Unmet Needs

11. Sjogren’s syndrome Emerging Therapies

12. Sjogren’s syndrome Market Outlook

13. Country-Wise Sjogren’s syndrome Market Analysis (2020–2034)

14. Sjogren’s syndrome Market Access and Reimbursement of Therapies

15. Sjogren’s syndrome Market drivers

16. Sjogren’s syndrome Market barriers

17. Sjogren’s syndrome Appendix

18. Sjogren’s syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sjogren’s Syndrome Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight

“FcRn Inhibitor Treatment Market”

(Albany, USA) DelveInsight’s FcRn Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, FcRn Inhibitor emerging, market share of individual therapies, and current and forecasted FcRn Inhibitor market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

The FcRn Inhibitor market size is anticipated to increase in the study period due to a direct consequence of an increase in R&D activity in the 7MM. Additionally, the competitive landscape is relatively sparse and the regulatory pathway for approval will likely involve extensive clinical trials to demonstrate safety and efficacy.

Request for Sample Report @ FcRn Inhibitor Market Forecast

Key Takeaways from the FcRn Inhibitor Market Report

• As per DelveInsight’s analysis, the FcRn market is anticipated to grow at a significant CAGR by 2034.
• The leading FcRn Inhibitor Companies such as argenX, UCB, Immunovant, Johnson & Johnson Innovative Medicine, and others.
• Some of the FcRn Inhibitor therapies include Vyvgart, Rystiggo, Batoclimab and others.
• In the full year 2023, the global net product revenues generated by VYVGART and VYVGART SC were USD 908 million and USD 246 million respectively.
• In April 2025, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART® Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
• In January 2025, Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.
• In September 2024, Immunovant Announced positive results from its Phase IIa trial of batoclimab in Graves’ Disease. Immunovant also announced alignment with the U.S. FDA and received Investigational New Drug Application (IND) clearance, with a pivotal trial of IMVT-1402 in Graves’ Disease which is also a FcRn inhibitor expected to initiate by December 2024 (Immunovant, 2024).
• In September 2024, Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of the Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking the first approval of nipocalimab for the treatment of people living with gMG.
• In October 2023, UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Discover which therapies are expected to grab the FcRn Inhibitor market share @ https://www.delveinsight.com/sample-request/fcrn-inhibitor-competitive-landscape-and-market-forecast

FcRn Inhibitor Overview

FcRn inhibitors are a novel class of therapeutic agents targeting the neonatal Fc receptor (FcRn), a protein crucial for regulating the half-life of immunoglobulin G (IgG) antibodies. FcRn normally protects IgG from lysosomal degradation, extending their lifespan in the bloodstream. By inhibiting FcRn, these drugs reduce IgG levels, offering a promising approach to treat autoimmune diseases where pathogenic autoantibodies play a critical role.

Conditions such as myasthenia gravis, pemphigus, and immune thrombocytopenia are characterized by autoantibodies that attack the body’s tissues. FcRn inhibitors lower these autoantibody levels, thereby mitigating disease symptoms. Key FcRn inhibitors in development or recently approved include efgartigimod and rozanolixizumab.

Efgartigimod, approved for generalized myasthenia gravis, has demonstrated significant efficacy in reducing IgG and improving clinical outcomes. Rozanolixizumab, another promising candidate, is being investigated for several autoimmune indications.

These drugs are generally well-tolerated, with common side effects including mild to moderate infections and headaches. The therapeutic potential of FcRn inhibitors is considerable, offering a targeted approach to modulating the immune system with fewer side effects compared to broad immunosuppressants. Ongoing research continues to expand their application, potentially transforming the management of numerous autoimmune conditions.

Learn more about the FDA-approved FcRn Inhibitor @ FcRn Inhibitor Drugs and Therapies

FcRn Inhibitor Treatment Market

The FcRn inhibitor treatment market has witnessed significant growth and attention in recent years due to its potential in addressing various autoimmune diseases and other related conditions. FcRn (neonatal Fc receptor) is a protein found in humans that plays a crucial role in the recycling of Immunoglobulin G (IgG) antibodies, which are important components of the immune system.

FcRn Inhibitor Companies and Drugs

• Vyvgart – argenX
• Rystiggo – UCB
• Batoclimab – Immunovant
• And Many Others

To know more about FcRn Inhibitor clinical trials, visit @ FcRn Inhibitor Companies and Medication

FcRn Inhibitor Market Dynamics

The FcRn Inhibitor market dynamics are anticipated to change in the coming years. The enriching drug pipeline of FcRn Inhibitor holds significant potential for large-scale companies to acquire a substantial market share, especially given the unique and rich emerging pipelines.

Furthermore, many potential therapies are being investigated for the treatment of FcRn Inhibitor, and it is safe to predict that the treatment space will significantly impact the FcRn Inhibitor market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the FcRn Inhibitor market in the 7MM.

The FcRn Inhibitor market dynamics have been evolving rapidly in recent years, driven by advancements in gene editing technology and increasing applications across various industries. FcRn Inhibitor (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of genetic engineering, offering precise and efficient tools for editing DNA sequences.

Scope of the FcRn Inhibitor Market Report

• Coverage- 7MM
• FcRn Inhibitor Companies– argenx SE (EBR: ARGX), UCB S.A. (EBR: UCB), Immunovant Inc. (NASDAQ: IMVT), and Johnson & Johnson Innovative Medicine, a division of Johnson & Johnson (NYSE: JNJ), among others.
• FcRn Inhibitor Therapies- Vyvgart, Rystiggo, Batoclimab and others.
• FcRn Inhibitor Therapeutic Assessment: FcRn Inhibitor current marketed and emerging therapies
• FcRn Inhibitor Market Dynamics: Attribute Analysis of Emerging FcRn Inhibitor Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• FcRn Inhibitor Unmet Needs, KOL’s views, Analyst’s views, FcRn Inhibitor Market Access and Reimbursement

Discover more about FcRn Inhibitor Drugs in development @ FcRn Inhibitor Clinical Trials and FDA Approvals

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary of FcRn Inhibitor

4. Key Events

5. FcRn Inhibitor Market Overview At A Glance

6. Background And Overview

7. FcRn Inhibitor Target Population

8. FcRn Inhibitor Marketed Drugs

9. FcRn Inhibitor Emerging Drugs

10. FcRn Inhibitor Market: The 7MM Analysis

11. FcRn Inhibitor Unmet Needs

12. FcRn Inhibitor SWOT Analysis

13. FcRn Inhibitor KOL Views

14. FcRn Inhibitor Market Access and Reimbursement

15. Appendix

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FcRn Inhibitor Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Revenue, Statistics, Therapies, and Companies by DelveInsight

“Cartilage Diseases Treatment Market”

(Albany, USA) DelveInsight’s “Cartilage Diseases Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cartilage Diseases Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The Cartilage Diseases market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Request for a Free Sample Report @ Cartilage Disease Market Insight

Some facts of the Cartilage Diseases Market Report:

• According to DelveInsight, Cartilage Diseases market is expected to grow at a decent CAGR by 2032.
• Leading Cartilage Diseases companies working in the treatment market are Regeneron, TissueGene, Vericel Corporation, Genzyme Corporation, Eli Lilly and Company, Incyte Corporation, Astellas Pharma, Pfizer, Sanofi, among others.
• Promising Cartilage Diseases therapies are Olumiant (Baricitinib), Celebrex (Celecoxib), Motrin (Ibuprofen), Kevzara (Sarilumab), and others.
• In November 2024, Tetec AG has announced a Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART Inject for the Treatment of Cartilage Defects in the Knee in Pediatric Patients With Closed Epiphyses
• In August 2024, Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size. MACI ArthroTM provides a less invasive technique compared to the current approach, allowing surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments.
• In August 2023, Biosolution Co., Ltd announced a Multi-Center, Open-Label, Phase 2 Trial to Evaluate the Efficacy and Safety of CartiLife® for Patients With Articular Cartilage Defects in the Knee

Cartilage Diseases Overview

Cartilage Disease, also known as cartilage disease, is related to multiple epiphyseal dysplasia and achondroplasia. Cartilage is a tough but flexible non-vascular type of supporting connective tissue that is found throughout the body. It covers the ends of bones at joints, and it also gives shape and support to body parts such as the ears, nose, and windpipe. Healthy cartilage helps joint articulation by allowing bones to glide smoothly over each other. It protects bones by preventing them from rubbing against each other. Cartilage disease can have major symptoms such as back pain, sciatica, and muscle cramp. Sports injuries, genetic factors, and different types of arthritis are some of the key causes of cartilage problems that may result in tears and injuries.

Learn more about Cartilage Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cartilage Disease Treatment Market

Cartilage Diseases Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cartilage Diseases market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Cartilage Diseases market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

The Cartilage Diseases market is primarily driven by the rising prevalence of osteoarthritis and other degenerative joint disorders, an aging global population, and the growing demand for minimally invasive treatment options. Advances in regenerative medicine, including stem cell and tissue engineering therapies, along with increased investments in research and development, are further propelling market growth. However, the market faces several barriers, such as the high cost of advanced therapies, limited availability of effective treatment options for late-stage cartilage damage, and stringent regulatory approval processes. Additionally, the lack of awareness and access to specialized treatment in developing regions poses a significant challenge to market expansion.

Explore more about Cartilage Disease Epidemiology @ Cartilage Disease Prevalence

Cartilage Diseases Epidemiology

The epidemiology section covers detailed insights into the historical and current Cartilage Diseases patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Cartilage Diseases Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cartilage Diseases market or expected to get launched in the market during the study period. The analysis covers Cartilage Diseases market uptake by drugs, patient uptake by therapies, and sales of each drug. Olumiant (Baricitinib): Eli Lilly and Company/Incyte Corporation

• Celebrex (Celecoxib): Astellas Pharma/Pfizer
• Motrin (Ibuprofen): Pfizer
• Kevzara (Sarilumab): Regeneron/Sanofi

Request for a sample report to understand more about the Cartilage Disease pipeline development activities @ Cartilage Disease Companies and Medication

Cartilage Diseases Therapeutics Assessment

Major key companies are working proactively in the Cartilage Diseases Therapeutics market to develop novel therapies which will drive the Cartilage Diseases treatment markets in the upcoming years are Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), TissueGene Inc. (KOSDAQ: 950160), Vericel Corporation (NASDAQ: VCEL), Genzyme Corporation (acquired by Sanofi), Eli Lilly and Company (NYSE: LLY), Incyte Corporation (NASDAQ: INCY), Astellas Pharma Inc. (TYO: 4503), Pfizer Inc. (NYSE: PFE), Sanofi (EPA: SAN), among others.

Learn more about the emerging therapies & key companies @ Cartilage Disease Clinical Trials and Drug Approvals

Cartilage Diseases Report Key Insights

1. Cartilage Diseases Patient Population

2. Cartilage Diseases Market Size and Trends3. Key Cross Competition in the Cartilage Diseases Market

4. Cartilage Diseases Market Dynamics (Key Drivers and Barriers)

5. Cartilage Diseases Market Opportunities

6. Cartilage Diseases Therapeutic Approaches

7. Cartilage Diseases Pipeline Analysis

8. Cartilage Diseases Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cartilage Diseases Market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Cartilage Diseases Competitive Intelligence Analysis

4. Cartilage Diseases Market Overview at a Glance

5. Cartilage Diseases Disease Background and Overview

6. Cartilage Diseases Patient Journey

7. Cartilage Diseases Epidemiology and Patient Population

8. Cartilage Diseases Treatment Algorithm, Current Treatment, and Medical Practices

9. Cartilage Diseases Unmet Needs

10. Key Endpoints of Cartilage Diseases Treatment

11. Cartilage Diseases Marketed Products

12. Cartilage Diseases Emerging Therapies

13. Cartilage Diseases Seven Major Market Analysis

14. Attribute Analysis

15. Cartilage Diseases Market Outlook (7 major markets)

16. Cartilage Diseases Access and Reimbursement Overview

17. KOL Views on the Cartilage Diseases Market.

18. Cartilage Diseases Market Drivers

19. Cartilage Diseases Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cartilage Diseases Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight

“Systemic Juvenile Idiopathic Arthritis Treatment Market”

(Albany, USA) DelveInsight’s “Systemic Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Systemic Juvenile Idiopathic Arthritis, historical and forecasted epidemiology as well as the Systemic Juvenile Idiopathic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Systemic Juvenile Idiopathic Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Systemic Juvenile Idiopathic Arthritis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Systemic Juvenile Idiopathic Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Systemic Juvenile Idiopathic Arthritis market.

Request for a Free Sample Report @ Systemic Juvenile Idiopathic Arthritis Market Forecast

Key highlights from the systemic juvenile idiopathic arthritis market report:

• The Systemic Juvenile Idiopathic Arthritis Market Size is anticipated to increase with a notable CAGR during the forecast period (2023-2032).
• The leading Systemic Juvenile Idiopathic Arthritis Companies such as Chugai Pharmaceutical, AstraZeneca, Pfizer, Incyte Corporation Novartis, Roche, Genentech, AbbVie, Pfizer, Eli Lilly and Company, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., UCB, Sanofi, and others are debveloping therapies for Systemic Juvenile Idiopathic Arthritis Treatment.
• Promising Systemic Juvenile Idiopathic Arthritis therapies are Actemra (Tocilizumab), Ilaris (Canakinumab), Adalimumab, Tofacitinib (Xeljanz), Baricitinib, and others.
• In February 2025, Eli Lilly and Company announced an Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
• In February 2025, AbbVie announced a Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis
• In January 2025, Sanofi announced an Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase
• In June 2024, AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now available as an option for these pediatric populations.
• In June 2024, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA), a form of arthritis that impacts multiple joints at a time.

Systemic Juvenile Idiopathic Arthritis Overview

Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare and severe subtype of juvenile idiopathic arthritis that affects children and adolescents. Unlike other forms of arthritis, sJIA is characterized by systemic inflammation that can impact not just the joints but also internal organs. Key symptoms of Systemic Juvenile Idiopathic Arthritis include spiking fevers, salmon-colored rash, fatigue, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. The exact cause of Systemic Juvenile Idiopathic Arthritis is unknown, but it is believed to involve genetic predisposition and immune system dysregulation.

Systemic Juvenile Idiopathic Arthritis is often challenging to diagnose due to overlapping features with other febrile illnesses and autoimmune diseases. Laboratory tests for Systemic Juvenile Idiopathic Arthritis typically show elevated inflammatory markers such as ESR, CRP, and ferritin. Treatment of Systemic Juvenile Idiopathic Arthritis includes NSAIDs, corticosteroids, and biologics like IL-1 and IL-6 inhibitors to control inflammation and prevent joint damage. Early diagnosis and targeted therapy can significantly improve outcomes in patients with Systemic Juvenile Idiopathic Arthritis. Long-term management of Systemic Juvenile Idiopathic Arthritis focuses on monitoring disease activity, minimizing medication side effects, and improving quality of life. Systemic Juvenile Idiopathic Arthritis requires multidisciplinary care involving rheumatologists, pediatricians, and physical therapists.

Learn more about Systemic Juvenile Idiopathic Arthritis, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Systemic Juvenile Idiopathic Arthritis Treatment Market

Systemic Juvenile Idiopathic Arthritis Market

The Systemic Juvenile Idiopathic Arthritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Systemic Juvenile Idiopathic Arthritis market trends by analyzing the impact of current Systemic Juvenile Idiopathic Arthritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology

This segment gives a thorough detail of the Systemic Juvenile Idiopathic Arthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Systemic Juvenile Idiopathic Arthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Systemic Juvenile Idiopathic Arthritis (sJIA) market is driven by several key factors, including the increasing prevalence of autoimmune and inflammatory disorders among children, advancements in biologic therapies, and growing awareness about early diagnosis and treatment. The development of targeted biologics, such as IL-1 and IL-6 inhibitors, has revolutionized the treatment landscape, providing more effective and safer options for managing sJIA. Additionally, rising healthcare expenditure, enhanced research and development activities, and improved access to healthcare facilities in emerging markets further contribute to the market growth.

However, the Systemic Juvenile Idiopathic Arthritis market also faces significant barriers. High costs associated with biologic therapies and limited reimbursement in some regions pose a major challenge for patient access. Moreover, delayed diagnosis due to the rarity and complex presentation of the disease can hinder timely treatment. The lack of awareness among general practitioners and inadequate specialized care infrastructure in underdeveloped regions also limit market expansion. Furthermore, potential side effects and long-term safety concerns related to immunosuppressive therapies can impact patient adherence. Despite these challenges, ongoing clinical trials, strong pipeline candidates, and collaborative efforts between pharmaceutical companies and healthcare organizations are expected to overcome some of these barriers and drive future growth in the Systemic Juvenile Idiopathic Arthritis market.

According to DelveInsight, the Systemic Juvenile Idiopathic Arthritis market in 7MM is expected to witness a major change in the study period 2019-2032.

Systemic Juvenile Idiopathic Arthritis Epidemiology

The Systemic Juvenile Idiopathic Arthritis epidemiology section provides insights into the historical and current Systemic Juvenile Idiopathic Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Systemic Juvenile Idiopathic Arthritis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Systemic Juvenile Idiopathic Arthritis Epidemiology at: Systemic Juvenile Idiopathic Arthritis Prevalence

Systemic Juvenile Idiopathic Arthritis Drugs Uptake

This section focuses on the uptake rate of the potential Systemic Juvenile Idiopathic Arthritis drugs recently launched in the Systemic Juvenile Idiopathic Arthritis market or expected to be launched in 2019-2032. The analysis covers the Systemic Juvenile Idiopathic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug

Systemic Juvenile Idiopathic Arthritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Systemic Juvenile Idiopathic Arthritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Systemic Juvenile Idiopathic Arthritis Pipeline Development Activities

The Systemic Juvenile Idiopathic Arthritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Systemic Juvenile Idiopathic Arthritis key players involved in developing targeted therapeutics.

Actemra (Tocilizumab) – Chugai Pharmaceutical/Roche

Actemra (Tocilizumab), an IL-6 blocker, is an important biologic treatment for Systemic Juvenile Idiopathic Arthritis (sJIA), successfully decreasing inflammation, fever, and joint injury. It is authorized for patients who do not respond sufficiently to traditional therapies, providing prolonged disease management and enhanced quality of life.

Ilaris (Canakinumab) – Novartis

Ilaris (Canakinumab), an IL-1β blocker, is a biological treatment authorized for Systemic Juvenile Idiopathic Arthritis (sJIA), addressing inflammation at its origin to alleviate fever, joint discomfort, and disease exacerbations.

Adalimumab – AbbVie/AstraZeneca

Adalimumab, a TNF-α blocker created by AbbVie and AstraZeneca, is prescribed for treating Systemic Juvenile Idiopathic Arthritis (sJIA) to decrease inflammation and avoid joint harm. It is delivered through subcutaneous injection, providing a targeted method for patients who do not respond sufficiently to standard treatments.

Tofacitinib (Xeljanz) – Pfizer

Tofacitinib (Xeljanz), a JAK inhibitor created by Pfizer, is being investigated as a therapeutic option for Systemic Juvenile Idiopathic Arthritis (sJIA) to minimize inflammation and disease activity

Request for a sample report to understand more about the Systemic Juvenile Idiopathic Arthritis pipeline development activities at: Systemic Juvenile Idiopathic Arthritis Companies and Medication

Systemic Juvenile Idiopathic Arthritis Therapeutics Assessment

Major key companies such as Chugai Pharmaceutical, AstraZeneca, Pfizer, Incyte Corporation Novartis, Roche, Genentech, AbbVie, Pfizer, Eli Lilly and Company, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., UCB, Sanofi, and others are working proactively in the Systemic Juvenile Idiopathic Arthritis Therapeutics market to develop novel therapies which will drive the Systemic Juvenile Idiopathic Arthritis treatment markets in the upcoming years.

Learn more about the emerging Systemic Juvenile Idiopathic Arthritis therapies & key companies at: Systemic Juvenile Idiopathic Arthritis Clinical Trials and Pipeline Analysis

Systemic Juvenile Idiopathic Arthritis Report Key Insights

1. Systemic Juvenile Idiopathic Arthritis Patient Population

2. Systemic Juvenile Idiopathic Arthritis Market Size and Trends

3. Key Cross Competition in the Systemic Juvenile Idiopathic Arthritis Market

4. Systemic Juvenile Idiopathic Arthritis Market Dynamics (Key Drivers and Barriers)

5. Systemic Juvenile Idiopathic Arthritis Market Opportunities

6. Systemic Juvenile Idiopathic Arthritis Therapeutic Approaches

7. Systemic Juvenile Idiopathic Arthritis Pipeline Analysis

8. Systemic Juvenile Idiopathic Arthritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Systemic Juvenile Idiopathic Arthritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Systemic Juvenile Idiopathic Arthritis Competitive Intelligence Analysis

4. Systemic Juvenile Idiopathic Arthritis Market Overview at a Glance

5. Systemic Juvenile Idiopathic Arthritis Disease Background and Overview

6. Systemic Juvenile Idiopathic Arthritis Patient Journey

7. Systemic Juvenile Idiopathic Arthritis Epidemiology and Patient Population

8. Systemic Juvenile Idiopathic Arthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Juvenile Idiopathic Arthritis Unmet Needs

10. Key Endpoints of Systemic Juvenile Idiopathic Arthritis Treatment

11. Systemic Juvenile Idiopathic Arthritis Marketed Products

12. Systemic Juvenile Idiopathic Arthritis Emerging Therapies

13. Systemic Juvenile Idiopathic Arthritis Seven Major Market Analysis

14. Attribute Analysis

15. Systemic Juvenile Idiopathic Arthritis Market Outlook (7 major markets)

16. Systemic Juvenile Idiopathic Arthritis Access and Reimbursement Overview

17. KOL Views on the Systemic Juvenile Idiopathic Arthritis Market

18. Systemic Juvenile Idiopathic Arthritis Market Drivers

19. Systemic Juvenile Idiopathic Arthritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Juvenile Idiopathic Arthritis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight

“Rheumatoid Arthritis Treatment Market”

(Albany, USA) DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market.

Discover which therapies are expected to grab the Rheumatoid Arthritis Market Share @ Rheumatoid Arthritis Market Outlook

Key Takeaways from the Rheumatoid Arthritis Market Report

• According to DelveInsight, Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2024–2034).
• Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period.
• Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023.
• In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023.
• The leading Rheumatoid Arthritis Companies such as Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others.
• Promising Rheumatoid Arthritis Therapies such as Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others.
• In February 2025, Inmedix® introduced its CloudHRV™ System to U.S. rheumatologists during the Rheumatology Winter Clinical Symposium held in Wailea, Maui. Cleared for commercialization by the U.S. FDA on January 17, 2025, the CloudHRV System is a heart rate variability (HRV) diagnostic tool intended for clinical use at the discretion of healthcare providers.
• In February 2025, Zydus Lifesciences received final approval from the U.S. FDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This combination therapy is prescribed for the relief of rheumatoid arthritis and osteoarthritis symptoms while also reducing the risk of upper gastrointestinal ulcers associated with long-term ibuprofen use.
• In January 2025, Celltrion, a prominent South Korean biopharmaceutical firm, announced U.S. FDA approval for its biosimilar Avtozma. Developed as a biosimilar to Actemra, Avtozma is available in both intravenous and subcutaneous forms and is indicated for autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and COVID-19.
• Additionally, in January 2025, Rise Therapeutics reported that the FDA accepted its Investigational New Drug (IND) application for a Phase 1 oncology trial of R-5780. The company continues to develop treatments targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
• In September 2024, Celltrion announced FDA approval for a Phase 3 clinical study of Zymfentra (CT-P13 SC, infliximab), its subcutaneous Remicade biosimilar, for rheumatoid arthritis treatment.
• June 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH).

Rheumatoid Arthritis Overview

Rheumatoid Arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and potential joint deformity. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Rheumatoid Arthritis symptoms typically include joint stiffness, swelling, fatigue, and reduced range of motion, often affecting the wrists, hands, and knees symmetrically.

Rheumatoid Arthritis diagnosis involves a combination of physical examinations, blood tests for inflammatory markers, and imaging techniques such as X-rays or MRIs to assess joint damage. Rheumatoid Arthritis progression can vary widely, with some individuals experiencing mild symptoms and others facing significant disability if left untreated

Rheumatoid Arthritis treatment focuses on controlling inflammation and slowing disease progression through medications such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), biologics, and corticosteroids. Rheumatoid Arthritis management may also include lifestyle changes, physical therapy, and in severe cases, surgical intervention.

Rheumatoid Arthritis research continues to advance, aiming for more targeted therapies and earlier diagnosis. Rheumatoid Arthritis awareness is essential for early detection and intervention, which can significantly improve long-term outcomes. Rheumatoid Arthritis patients benefit from a multidisciplinary approach involving rheumatologists, physical therapists, and support groups to enhance quality of life and manage daily challenges.

Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Rheumatoid Arthritis Treatment Market

Rheumatoid Arthritis Epidemiology

The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions.

Rheumatoid Arthritis Epidemiology Segmentation:

• Total Prevalence of Rheumatoid Arthritis
• Prevalent Cases of Rheumatoid Arthritis by severity
• Gender-specific Prevalence of Rheumatoid Arthritis
• Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis

Download the report to understand which factors are driving Rheumatoid Arthritis Epidemiology trends @ Rheumatoid Arthritis Prevalence

Rheumatoid Arthritis Marketed Drugs

• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis

• RINVOQ (upadacitinib): AbbVie

RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.

Rheumatoid Arthritis Emerging Drugs

• Rabeximod (Rob 803): Cyxone

Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in rheumatoid arthritis.

• Imvotamab: IGM Biosciences

Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells.

Rheumatoid Arthritis Market Outlook

Rheumatoid Arthritis aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA.

Request for a sample report to understand more about the Rheumatoid Arthritis pipeline development activities at: Rheumatoid Arthritis Companies and Medication

Rheumatoid Arthritis Drug Market

The pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis.

Scope of the Rheumatoid Arthritis Market Report

• Coverage- 7MM
• Rheumatoid Arthritis Companies- Major pharmaceutical and biotechnology companies such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), UCB BIOSCIENCES GmbH (part of UCB S.A., EBR: UCB), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Changchun GeneScience Pharma (SHE: 000661), Novartis (SWX: NOVN), Istituto Giannina Gaslini, and others.
• Rheumatoid Arthritis Therapies- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others.
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers
• Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Rheumatoid Arthritis Drugs in development @ Rheumatoid Arthritis Clinical Trials Assessment and Pipeline Analysis

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Flow Methodology

6 Rheumatoid Arthritis Market Overview at a Glance

7 Disease Background and Overview

8 Treatment and Management of Rheumatoid Arthritis

9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology)

10 Treatment Guidelines for RA (National Institute for Health and Care Excellence)

11 Guidelines for Management of RA (American College of Rheumatology)

12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology)

13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR))

14 Treatment Algorithm

15 Epidemiology and Patient Population of 7MM

16 Patient Journey

17 Key Endpoints in Rheumatoid Arthritis Clinical Trials

18 Marketed Drugs

19 Emerging Drugs

20 Rheumatoid arthritis: 7MM Market Analysis

21 Unmet Needs

22 SWOT Analysis

23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies

24 KOL Views

25 Appendix

26 DelveInsight Capabilities

27 Disclaimer

28 About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight